
Aytu BioScience AYTU
$ 2.66
0.0%
Aytu BioScience Total Current Liabilities | AYTU
Annual Total Current Liabilities Aytu BioScience
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.7 M | 63.1 M | 62.2 M | 69 M | 64.4 M | 109 M | 28.3 M | 5.37 M | 3.39 M | 3.61 M | 10.1 M | 1.48 M | - | 121 K | 82.4 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 82.4 K | 34 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Seres Therapeutics
MCRB
|
19.3 M | $ 1.25 | -6.02 % | $ 11.1 M | ||
|
Oramed Pharmaceuticals
ORMP
|
19.1 M | $ 3.58 | -2.98 % | $ 148 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
310 M | $ 378.19 | -4.68 % | $ 8.48 B | ||
|
CEL-SCI Corporation
CVM
|
5.13 M | $ 1.2 | -18.37 % | $ 9.62 M | ||
|
MeiraGTx Holdings plc
MGTX
|
123 M | $ 7.98 | -1.97 % | $ 642 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
13.5 B | $ 39.21 | 1.76 % | $ 44.9 B | ||
|
Eton Pharmaceuticals
ETON
|
38.5 M | $ 60.77 | -0.96 % | $ 1.64 B | ||
|
IDEAYA Biosciences
IDYA
|
58.8 M | $ 25.52 | -2.48 % | $ 2.26 B | ||
|
Protalix BioTherapeutics
PLX
|
26.5 M | $ 2.89 | -5.56 % | $ 227 M | ||
|
Lantern Pharma
LTRN
|
4.5 M | $ 0.25 | -13.67 % | $ 2.72 M | ||
|
Foghorn Therapeutics
FHTX
|
59.7 M | $ 1.71 | -3.93 % | $ 108 M | ||
|
Ocugen
OCGN
|
23 M | $ 0.77 | 4.74 % | $ 241 M | ||
|
Minerva Neurosciences
NERV
|
2.29 M | $ 2.03 | -4.25 % | $ 17.2 M | ||
|
Neurocrine Biosciences
NBIX
|
743 M | $ 150.5 | -3.89 % | $ 15 B | ||
|
Prothena Corporation plc
PRTA
|
40.8 M | $ 8.12 | -3.33 % | $ 437 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
44.9 M | $ 6.99 | -2.85 % | $ 1.01 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
20.9 M | $ 1.53 | -8.68 % | $ 555 M | ||
|
Moleculin Biotech
MBRX
|
6.85 M | $ 7.73 | -2.59 % | $ 9.16 M | ||
|
Nurix Therapeutics
NRIX
|
86.5 M | $ 12.88 | -5.29 % | $ 1.12 B | ||
|
Nkarta
NKTX
|
22.3 M | $ 1.14 | 1.34 % | $ 84.3 M | ||
|
MacroGenics
MGNX
|
43.1 M | $ 1.97 | -0.76 % | $ 124 M | ||
|
Protagonist Therapeutics
PTGX
|
45.4 M | $ 121.72 | -2.2 % | $ 7.74 B | ||
|
Marker Therapeutics
MRKR
|
2.27 M | $ 1.1 | -17.05 % | $ 16.8 M | ||
|
Arcus Biosciences
RCUS
|
231 M | $ 15.62 | -1.01 % | $ 1.68 B | ||
|
Replimune Group
REPL
|
58.2 M | $ 19.07 | -0.83 % | $ 1.77 B | ||
|
NextCure
NXTC
|
6.41 M | $ 6.62 | -2.43 % | $ 35.2 M | ||
|
Rocket Pharmaceuticals
RCKT
|
30.2 M | $ 1.95 | -7.82 % | $ 217 M | ||
|
PMV Pharmaceuticals
PMVP
|
11.4 M | $ 0.87 | -33.79 % | $ 45.7 M | ||
|
United Therapeutics Corporation
UTHR
|
561 M | $ 553.08 | -1.08 % | $ 24.5 B | ||
|
Olema Pharmaceuticals
OLMA
|
51.8 M | $ 7.0 | -2.1 % | $ 609 M | ||
|
Kymera Therapeutics
KYMR
|
83.2 M | $ 115.19 | -3.52 % | $ 9.73 B | ||
|
Oragenics
OGEN
|
1.8 M | $ 0.16 | -6.16 % | $ 345 K | ||
|
Ovid Therapeutics
OVID
|
8.29 M | $ 2.2 | -5.98 % | $ 286 M | ||
|
Passage Bio
PASG
|
20.7 M | $ 3.94 | 9.14 % | $ 12.6 M | ||
|
Vaxcyte
PCVX
|
206 M | $ 55.37 | -5.12 % | $ 7.54 B | ||
|
Relay Therapeutics
RLAY
|
25.6 M | $ 16.11 | 1.26 % | $ 2.76 B | ||
|
Precigen
PGEN
|
37.3 M | $ 4.21 | 1.08 % | $ 1.32 B | ||
|
Avidity Biosciences
RNA
|
195 M | $ 6.94 | -0.57 % | $ 956 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
1.02 M | $ 0.66 | -7.55 % | $ 3.95 M | ||
|
Praxis Precision Medicines
PRAX
|
59.8 M | $ 300.01 | -3.5 % | $ 6.75 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
53 M | $ 3.22 | -1.08 % | $ 248 M | ||
|
Ocular Therapeutix
OCUL
|
50.8 M | $ 5.57 | -5.03 % | $ 1.04 B | ||
|
Sana Biotechnology
SANA
|
78.7 M | $ 1.58 | -9.2 % | $ 400 M |